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Dear Editor,
The prevalence of nontuberculous mycobacterial (NTM) infec-
tion worldwide has increased, and lung is the most heavily
affected organ.1 Because NTM and Mycobacterium tuberculosis
(MTB) are both acid-fast bacilli (AFB), it is difﬁcult to distin-
guish them using the AFB test alone, and drug treatment for
NTM is totally different from anti-tuberculosis (TB) therapy.
There is a high incidence of pulmonary TB in China,2 but Chi-
nese hospitals still use positive AFB test, clinical symptoms,
and chest radiographic abnormalities as the key diagnostic
criteria for pulmonary TB. Therefore, there is a high risk of
NTM pulmonary infection being misdiagnosed and incorrectly
treated.3 In order to investigate the prevalence, clinical char-
acteristics and risk factors of NTM infection in patients who
met  Chinese pulmonary TB diagnostic criteria, we  performed
this study in Zhejiang Province, southeastern China.
This investigation was conducted prospectively in sentinel
sites of 12 counties in Zhejiang from January 2011 to December
2013. All the sentinel sites are part of a laboratory and hospital
network, the Chinese Demonstration Zone of the prevention
and treatment of infectious diseases, which was set for sys-
tematic surveillance of pulmonary TB.3 The laboratories and
hospitals collected the sputum samples and clinical data of
HIV negative suspected pulmonary TB patients and performed
mycobacterial culture and AFB test. The AFB-positive isolates
were sent to central laboratory, and ﬁrst tested using a Capital-
Bio Mycobacterium identiﬁcation microarray.3,4 The identiﬁed
NTM strains were then further tested by sequencing of 16S
rRNA, heat shock protein 65 (hsp65), and the RNA polymerase
beta-subunit-encoding (rpoB) genes and then compared by
BLAST analysis. NTM pulmonary disease was diagnosed based
on criteria proposed by the American Thoracic Society (AST)
guidelines.5
SPSS version 19.0 was used for the statistical analyses. The
Cochran-Armitage trend test was used to evaluate the annual
incidence of NTM pulmonary isolates. The distributions of
smoking, alcohol abuse, bronchiectasis, pulmonary emphy-
sema, chronic bronchitis, and living and working conditionsbetween males and females were compared using the 2 test.
The independent risk factors affecting patient outcome was
identiﬁed by logistic regression analysis including all patients.
Results were considered statistically signiﬁcant when p-value
<0.05.
A total of 1953 AFB-positive mycobacterial isolates were
cultured from the sputum samples of 1831 suspected pul-
monary TB patients, whereas 113 NTM strains from 100
patients were identiﬁed. Eleven patients met  the AST bacte-
riological criteria for NTM pulmonary disease; three patients
had no clinical symptoms or chest radiography abnormality,
and their isolates might have been contaminants or transient
colonization; other 86 patients had positive clinical symptoms
or chest radiography abnormalities, though the number of
respiratory isolates were insufﬁcient. Nineteen patients had
repeatedly negative AFB tests of their sputum but had posi-
tive culture results, none of them met  NTM pulmonary disease
diagnostic criteria.
Microarray biochip identiﬁcation showed that there
were 55 Mycobacterium intracellulare and eight Mycobacterium
avium isolates, 25 Mycobacterium kansasii, one Mycobacterium
malmoense/szulgai,  16 Mycobacterium abscessus/chelonei, one
Mycobacterium gilvum,  four Mycobacterium fortuitum, and three
NTM without species identiﬁcation. Direct sequencing were
performed in 106 NTM isolates, and out of those six iso-
lates were not consistent with biochip identiﬁcation results,
including three Mycobacterium marinum, one Mycobacterium sp.
JDM601, one Mycobacterium smegmatis,  and one M. gilvum.
The patient clinical characteristics are shown in Table 1.
Multiple logistic regression analysis determined that history
of steroid use to be the only independent risk factor affect-
ing patient prognosis. Of the eight patients using steroids, ﬁve
received anti-NTM therapy while the other three died. The
local hospitals did not report the indications or details for the
steroid treatment, making it difﬁcult to explain this risk factor,
which may be associated with the therapy used for end-stage
pneumonia patients.
The prevalence of pulmonary TB cases in the 12 counties
was 62.1 per 100,000 in 2011, 68.6 per 100,000 in 2012, 59.2 per
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Table 1 – Patient clinical characteristics.
Characteristic, N = 100 Value
Age, X¯  ± SD (years) 58.3 ± 17.1
Sex, female, N (%) 32 (32.0%)
BMI, X¯ ± SD (kg/m2) 20.5 ± 2.9
Rural residents, N (%) 63 (63.0%)
Manual workers or farmers, N (%) 62 (62.0%)
Transient population*, N (%) 11 (10.5%)
AFB negative, N (%) 19 (19.0%)
Aged male rural residents, N (%) 34  (34.0%)
Young transient male manual workers, N (%) 11  (10.5%)
Non-smoking aged female, N (%) 30  (30.0%)
Comorbidities, N (%)
Steroid use‡ 8 (8.0%)
Alcohol abuse 6 (6.0%)
Smoking* 23 (23.0%)
Bronchiectasis* 6 (6.0%)
Pulmonary emphysema* 14 (14.0%)
Chronic bronchitis 18 (18.0%)
Silicosis 1 (1.0%)
Hypertension 8 (8.0%)
Liver cirrhosis 3 (3.0%)
Diabetes 2 (2.0%)
Radiographic manifestation, N (%)
Pulmonary cavities 43 (43.0%)
Bilateral involvement 47 (47.0%)
Receiving anti-TB therapy, N (%) 72 (72.0%)
Receiving anti-NTM therapy, N (%) 19 (19.0%)
Anti-NTM therapy duration, X¯ ± SD (months) 6.5 ± 6.6
Total mortality, N (%) 12 (12.0%)
‡ Steroid use was the independent risk factor affecting patient out-
come, p < 0.05, adjusted OR = 0.14, CI: 0.02, 0.87.
∗ The distributions of smoking, pulmonary emphysema, tran-
sient population and bronchiectasis were signiﬁcantly different
between male and female patients, p < 0.05.
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500,000 in 2013. As the local population was close to 71.8 mil-
ion, the annual incidence of NTM infected patients and NTM
ulmonary diseases could be estimated. In 2011 they were 3.07
nd 0.43 per 100,000, in 2012 were 3.92 and 0.48 per 100,000, in
013 were 3.36 and 0.17 per 100,000. The differences of annual
ncidence were not statistically signiﬁcant (p > 0.05).
In conclusion, we  found that there was a high possibility
hat NTM pulmonary infected patient might be misdiagnosed
s pulmonary tuberculosis by Chinese pulmonary tuberculo-
is diagnostic criteria. In addition, aged male rural residents,
oung male manual transient workers, and aged non-smoking
emale were three distinct patient groups. Physicians should
ifferentiate NTM pulmonary disease carefully from pul-
onary TB.5;1 9(6):670–671 671
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